ScripThe end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D
ScripAlumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the
ScripDespite an earlier Phase III failure, Savara Inc. has stuck with its goal to bring recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) to approval in autoimmune pulmonary alv
ScripApogee Therapeutics, Inc. and Sagimet Biosciences, Inc. saw nothing unlucky about launching their initial public offerings on the 13th day of July, marking the first big biopharmaceutical company I